Aurobindo Pharma Ltd (AUROPHARMA)

Aurobindo Pharma Leads in Active Drug Shortages in US Market - 30 Apr, 2024

Aurobindo Pharma, Sun Pharmaceutical Industries, and Gland Pharma are projected to make significant strides in the US market due to elevated levels of active drug shortages. Aurobindo Pharma leads with 36 products under shortage, followed by Sun Pharmaceutical Industries and Gland Pharma. Jeewani and Bagrecha recommend Aurobindo Pharma as the preferred choice among export-oriented generic manufacturers.

Aurobindo Pharma Stock Shows Strong Performance - 29 Apr, 2024

Aurobindo Pharma's stock has shown strong performance, with an 86.54% increase in the last year and a 1.79% increase on the NSE today. The company is also among several pharma stocks that have given a strong breakout.

Private Companies Hold 37% Stake in Aurobindo Pharma - 28 Apr, 2024

A significant proportion of Aurobindo Pharma Limited is owned by private companies, with the top five shareholders holding a majority stake. Institutional investors also have a fair amount of ownership, indicating credibility in the investment community. Insiders own a meaningful ₹101b stake in this ₹663b business, while the general public owns a 15% stake.

Investec Maintains Buy Rating on Aurobindo Pharma - 25 Apr, 2024

Investment bank Investec has maintained a buy rating on Aurobindo Pharma with a target price of Rs 1350. The bank expects earnings momentum to sustain as the company is a big beneficiary of the US generic macro improvement, and a ramp up in PenG production is likely to aid earnings momentum.

Aurobindo Pharma Sees Increase in Revenue and Profit; ICICI Sets Target Price - 17 Apr, 2024

Aurobindo Pharma sees a rise in revenue and net profit during Q3FY24. ICICI Prudential Mutual Fund acquires 3.60% stake. ICICI Securities sets target price of Rs 1,270 with potential 15% return.

Aurobindo Pharma Reports Q4FY24 Results and Promoter Pledge Increase - 16 Apr, 2024

Aurobindo Pharma reports a growth in consolidated total income and net profit after tax for Q4FY24. Additionally, promoters increased their pledge on company holdings.

Aurobindo Pharma Shares Drop Over 2% After USFDA Observations - 15 Apr, 2024

Aurobindo Pharma's Eugia Sterile unit received three critical observations from the USFDA, citing shortcomings in key areas of plant operations and raising concerns about drug product contamination. The company is expected to address these promptly to maintain regulatory compliance.

Aurobindo Pharma's P/E Ratio May Be Sending Bullish Signals - 10 Apr, 2024

Aurobindo Pharma Limited has a P/E ratio of 23.9x, which is lower than the average for Indian companies. However, further analysis is needed to determine if this reduced P/E is justified.

Aurobindo Pharma Receives Observations from USFDA; Reports Fatal Accident at Subsidiary Facility - 08 Apr, 2024

Aurobindo Pharma received three observations from the USFDA on its Andhra Pradesh subsidiary's new injectable facility. Unfortunately, one person died in an accident at the company's wholly-owned subsidiary in Andhra Pradesh. The stock fell by 1.5%.

Aurobindo Pharma Reports 90.6% YoY Rise in Net Profit - 07 Apr, 2024

Aurobindo Pharma reported a consolidated net profit of Rs 936.2 crore for Q3 FY24, up by 90.6% YoY. The company appointed T. Vijaya Kumar as President - R&D (Specialty Drug Delivery). Aurobindo Pharma had a net capex of $103 million, including $37 million towards its bulk drugs PLI project. Total investment for the PLI project is $230 million while in biosimilar project it is $305 million as of December 31, 2023. Total R&D spend for the quarter is Rs 398 crore.

Aurobindo Pharma Commissions Four Manufacturing Facilities - 06 Apr, 2024

Aurobindo Pharma has commissioned four manufacturing facilities in Andhra Pradesh, including a Penicillin G plant, to boost self-reliance in the pharmaceutical sector. The company's revenue increased by 1.8% from Rs. 7,219 crores during the September quarter to Rs. 7,352 crores in the December quarter. Additionally, net profits rose by 25% from Rs. 752 crores to Rs. 940 crores during the same period.

Aurobindo Pharma Injectable Facility Inspected by US FDA - 05 Apr, 2024

The United States Food and Drug Administration (FDA) inspected Aurobindo Pharma's newly operational injectable facility in Andhra Pradesh and issued three procedural observations. The company stated that it will address the observations within the stipulated timeframe.

Aurobindo Pharma Q3 Net Profit Up by 109% - 03 Apr, 2024

Aurobindo Pharma records a net profit of Rs 623.8 crore for the December quarter, up by 109% YoY. Operating profit margins also improved from 13.79% to 17.89%. Axis Direct maintains a buy rating on the stock due to its strong earnings and expansion plans.

Aurobindo Pharma Commissions Four Manufacturing Facilities - 02 Apr, 2024

Aurobindo Pharma has commissioned four cutting-edge manufacturing facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), Injectable products, and Granulation. The Penicillin-G facility in Andhra Pradesh has a capacity of 15,000 tonne per annum and is expected to start trial production in April.

Aurobindo Pharma Commissions Four Manufacturing Facilities - 01 Apr, 2024

Aurobindo Pharma has commissioned four cutting-edge production facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), injectable medicines, and granulation through its wholly-owned subsidiaries. The Penicillin-G facility in Kakinada SEZ area has the ability to create 15,000 tonnes annually and was approved under the Production Linked Incentive Program. Shares rose by 4%.